DataM Intelligence | competitive Intelligence ITP affects 2–5/100k yearly. New therapies like BTK, FcRn blockers aim for lasting remission, ...

With its existing entitlement, plus the newly acquired economics from BioInvent, XOMA Royalty will be entitled to milestones of up to USD $16.25 million from Takeda and mid-single digit royalties on ...

One emerging treatment option for several antibody-mediated autoimmune diseases is the anti-CD38 antibody daratumumab, which depletes autoantibody-secreting plasma cells. Methods We treated two ...

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

New data from the IRAKLIA and IZALCO trials, presented at the 2025 ASCO Annual Meeting, demonstrate that subcutaneous ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing ...

Glenmark's cancer drug delivers high response in phase-1 trial, shows 74% response: Our Bureau, Mumbai Tuesday, June 3, 2025, 16:45 Hrs [IST] Ichnos Glenmark Innovation (IGI), a g ...

The MATTERHORN trial showed improved EFS and OS with durvalumab plus chemotherapy in gastric/GEJ cancer patients compared to chemotherapy alone. Durvalumab treatment resulted in a higher pCR rate ...

CLOVIS — It was a relatively quiet day of protest outside the CIF State track and field championship prelims Friday afternoon, with just a handful of demonstrators standing with signs outside of ...

CLOVIS — It was a relatively quiet day of protest outside the CIF State track and field championship prelims Friday afternoon, with just a handful of demonstrators standing with signs outside of ...